Results 101 to 110 of about 12,992 (201)

Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome [PDF]

, 2017
Background: Kidney transplantation in patients with atypical haemolytic uraemic syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in graft loss. Eculizumab prophylaxis prevents recurrence, improving graft survival.
Wetzels, J.F.M., Brand, J. van den, Adang, E.M.M., Verhave, J.C.   +3 more
core   +1 more source

An Approach to Antibody‐Mediated Rejection in Pediatric Liver Transplantation

Pediatric Transplantation, Volume 30, Issue 9, September 2026.
ABSTRACT Antibody‐mediated rejection (AMR) is an important but infrequent cause of pediatric liver allograft injury. There is a lack of standardized guidance, and treatment approaches vary across institutions. A writing group from the Society of Pediatric Liver Transplantation conducted a comprehensive review of the published literature and collected ...
Catalina Jaramillo, Parmjeet Randhawa, Amrita Narang, Alison J. Gareau, Jody Weckwerth, Alisha Mavis, George Mazariegos, Katryn Furuya, Nanda Kerkar   +8 more
wiley   +1 more source

Xenotransplantation of the Porcine Lung—From Immunological Barriers to Emerging Experimental Strategies

Xenotransplantation, Volume 33, Issue 5, September/October 2026.
ABSTRACT Lung transplantation is the only long‐lasting life‐saving treatment for patients with end‐stage pulmonary disease, but the ever‐growing shortage of suitable donor organs leads to high mortality rates of the afflicted patients. Xenotransplantation, the transplantation of organs across species, has emerged as a promising alternative. This review
Nathalie Roters, Niveditha Varma, Robert Ramm, Heiner Niemann, Patrick Zardo, Arjang Ruhparwar, Tobias Goecke   +6 more
wiley   +1 more source

Eculizumab in secondary atypical haemolytic uraemic syndrome [PDF]

, 2017
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.
Jarque, Ana, Portoles, Jose, Gonzalez-Parra, Emilio, Portolés Pérez, José María, Ávila, Ana, Sevillano, Ángel, Romera, Ana María, Borrego, Josefa, Quintana, Luis F, María Romera, Ana, Mendizabal, Santiago, Aljama, Pedro, Gavela, Eva, Macía, Manuel, Quintana, Luis F., Morales, Enrique, Gracia-Iguacel, Carolina, Rojas-Rivera, Jorge, Rodriguez-de-Cordoba, Santiago, Rodríguez de Córdoba, Santiago, Espinosa, Mario, Huerta, Ana, González Parra, Emilio José, Román, Elena, Arjona, Emi, Rabasco, Cristina, López, Antía, Blasco, Miquel, Cavero, Teresa, Fuentes, Carolina, Praga, Manuel, Cao, Mercedes, Praga Terente, Manuel, Gracia Iguacel, Carolina Marta, García, Alba   +34 more
core   +1 more source

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

Frontiers in Pediatrics
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement ...
Xin Wei, Xinzhu Liu, Yingying Yu, Wei Xie, Wentao Luo, Ye Tu, Shuhong Bu, Guimei Guo   +7 more
doaj   +1 more source

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj   +1 more source

Pregnancy in PNH: another eculizumab baby.

, 2010
Pregnancy in PNH: another eculizumab ...
Notaro R, Santachiara R, COLUCCIO, Valeria, TORELLI, Giuseppe, Leonardi G, Luzzatto L., MARASCA, Roberto   +6 more
core   +1 more source

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome

, 2016
Lilian M Pereira Palma,1 Craig B Langman2  1Pediatric Nephrology, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil; 2The Feinberg School of Medicine, Northwestern University, and the Ann and Robert H.
Palma LMP, Langman CB
core  

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

, 2006
Item does not contain fulltextBACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal ...
Christopher F. Mojcik, Mojcik, C.F., Young, N.S., Antonio M. Risitano, Chieh-Lin Fu, Browne, P., Jörg Schubert, Luzzatto, L., Elebute, M.O., Maciejewski, J, Russell P. Rother, Fu, C.L., Jeffrey Szer, Socie, G., Hubert Schrezenmeier, Rollins, S.A., Anita Hill, Szer, J., Schrezenmeier, H., Modupe O. Elebute, Jaroslaw Maciejewski, Nakamura, R., Roth, A., Maciejewski, J.P., Alexander Röth, Rother, R.P., Brodsky, R.A., Gerard Socié, Lucio Luzzatto, Ryotaro Nakamura, Schubert, J., Paul Browne, Hillmen, P., Peter Hillmen, Hill, A., Petra Muus, Scott A. Rollins, Neal S. Young, Muus, P., Robert A. Brodsky, Risitano, A.M.   +40 more
core   +1 more source

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

Case Reports in Transplantation, 2017
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic
Luca Lanfranco, Melanie Joly, Arnaud Del Bello, Laure Esposito, Noelle Cognard, Peggy Perrin, Bruno Moulin, Nassim Kamar, Sophie Caillard   +8 more
doaj   +1 more source